

- **01.31.23 - Casma Therapeutics Announces CEO Transition (PR)**
  - Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., has stepped down as Chief Executive Officer, effective January 13, 2023. Dr. Dionne will continue to serve on the Board of Directors. Frank Gentile, Ph.D., formerly Chief Operating Officer of Casma, has been appointed as the new Chief Executive Officer and will also serve on the Board of Directors.
- **01.31.23 - Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer (PR)**
  - Mr. Kane brings more than three decades of experience in the pharmaceutical industry. He's held senior level commercial positions at leading biopharma companies, Allergan, Pfizer, and Sepracor (now Sunovion Pharmaceuticals), and was an integral part of launching several successful brands, including CELEBREX® for the treatment of arthritis, NAMZARIC® for Alzheimer's disease, VRAYLAR® for the treatment of schizophrenia and bipolar disorder, and UBRELVY™, the first oral calcitonin gene-related peptide (CGRP) for the acute treatment of migraine. Most recently, he was the executive vice president and chief commercial officer at BioXcel Therapeutics.
- **01.31.23 - Optinose Announces CEO Transition and Business Update Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors (PR)**
  - During Mr. Miller's nearly 13 years as CEO, the Company experienced significant growth. His leadership led to the successful development and out-licensing of the Company's first product, ONZETRA Xsail®, becoming a public company listed on Nasdaq, and the transition from a clinical-stage company to a commercial-stage company through the successful development, FDA approval and commercialization of XHANCE®. Dr. Mahmoud, the Company's President and Chief Operating Officer since 2010, will succeed Mr. Miller as the new CEO of Optinose and as a Board member, effective immediately. Dr. Mahmoud has led both the commercial and R&D functions during his tenure at Optinose and has been instrumental to the successful development and FDA approval of all Company products, including XHANCE, during this time, and for the clinical research program supporting the potential first-ever approval of a drug product for chronic sinusitis.
- **01.30.23 - Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors (PR)**
  - Ms. Silverstein is a seasoned finance executive with experience across both private and public biopharmaceutical companies and an aptitude for implementing strong financial strategy, corporate partnering, financial reporting, cash management and improving efficiencies within organizations. Ms. Silverstein currently serves as CFO of Excision Biotherapeutics, Inc., and most recently served as CFO of Emendo Biotherapeutics (acquired in December 2020 by AnGes, Inc.). She previously operated in various senior executive roles within the biotechnology industry, including Abeona Therapeutics, as CFO and Principal Financial Officer, and SCO Capital Partners, a New York-based biotechnology venture fund, as managing director. Ms. Silverstein began her career in the financial services industry before moving to capital markets advisory firms, where she was instrumental in advising clients on transaction considerations and formulating effective U.S. public listing and financing strategies.
- **01.31.23 - Kinnate Biopharma Adds Global Business and Oncology Expertise to Board of Directors (Pharmatechfocus)**
  - Most recently, Ms. DeSimone served as President of U.S. Oncology at Merck & Co., Inc., where she established the company's oncology division, growing it from less than \$500 million in annual revenue to \$9 billion in just eight years. She led three key product launches and more than 45 indication launches, including Keytruda®, the fastest growing product in company history. Prior to joining Merck, Ms. DeSimone was Senior Vice President of Global Women's Health at Teva Pharmaceutical Industries, Ltd., where she built its first global business unit. Ms. DeSimone began her career at Bristol Myers Squibb and held roles of increasing responsibility culminating as the Senior Vice President of U.S. Oncology, a role in which she helped launch the first FDA-approved CTLA-4 immune checkpoint inhibitor, Yervoy®. Ms. DeSimone currently serves as a board member for Oncternal Therapeutics, a clinical-stage oncology company, Affini-T Therapeutics, an immune-oncology cell therapy company, the Florida Cancer Specialists Foundation, a nonprofit organization that delivers non-medical aid for individuals undergoing treatment for cancer, and Praxis Precision Medicines, Inc., a clinical-stage company focused on development of therapies for the central nervous system.
- **01.30.23 - Aprea Therapeutics Appoints John Hamill as Chief Financial Officer**
  - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of John Hamill as Chief Financial Officer. Mr. Hamill joins Aprea with more than 30 years of finance and accounting experience.
- **01.26.23 - Shawn Levy Elevated to Chief Scientific Officer and Senior Vice President of Applications (PR)**
  - Element Biosciences, Inc.— the developer of an innovative DNA sequencing platform disrupting genomics — announced the promotion of Shawn Levy, PhD, to Chief Scientific Officer and Senior Vice President of Applications. Prior to joining Element, Shawn spent over 20 years in academia where he developed and led a number of core facilities and genome centers while a faculty member at Vanderbilt University and HudsonAlpha Institute for Biotechnology.

- **01.26.23 - Apogee Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer (PR)**
  - Ms. Henderson has an extensive track record in financial and corporate strategy leadership, including financing private and public companies, partnering and M&A, and building teams and operations. Prior to joining Apogee, Ms. Henderson served as Chief Financial Officer and Chief Business Officer at Invivyd Therapeutics where she led the company's Series C crossover financing and subsequent IPO.
- **01.25.23 - Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer (PR)**
  - Ms. Cheung joins Pliant from SyntheKine, a privately held biotechnology company. Prior to this, Ms. Cheung served as Vice President of Human Resources at Rigel Pharmaceuticals, where she supported an integrated research, development and commercial-stage organization. Prior, she held positions of increasing responsibilities at Actelion Pharmaceuticals, Inc. (now Janssen Pharmaceuticals, a Johnson & Johnson Company) and held human resources roles at Covad Communications, National Semiconductor and United Behavioral Health. Ms. Cheung received her B.S. in Management from San Francisco State University.
- **01.23.23 - Cue Biopharma Announces Chief Medical Officer Transition (PR)**
  - Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023. Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory role. s acting CMO, Dr. Pienta not only helped bring two cancer drug candidates to the clinic, CUE-101 and CUE-102, but also established a network of top tier clinical sites in collaboration with leading clinicians, principal investigators and key opinion leaders.
- **01.19.23 - Cardurion Pharmaceuticals Strengthens Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer (PR)**
  - Ms. Radcliffe has significant experience across a range of biopharmaceutical R&D, commercial and business operations at large and small organizations, including both public and private companies. Most recently, she served as Chief Financial Officer at Affinivax, Inc., where she helped to transition the company from a preclinical to late-stage clinical organization and ultimately played a key role in the Company's sale to GSK plc for up to \$3.3 billion. Ms. Radcliffe's earlier leadership roles included serving as Vice President, Finance and Strategy and Treasurer at Arrakis Therapeutics, and as Vice President, Financial Planning & Analysis at Agios Pharmaceuticals. She spent over a decade at Biogen serving in a wide array of roles, including Head of R&D Finance where she led financial planning and accounting for the worldwide R&D and medical affairs functions.
- **01.19.23 - Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer (PR)**
  - An experienced biopharmaceutical executive and physician, Dr. Heller brings a deep understanding of the successful development of novel oncology medicines. Previously he served as executive vice president, research and development at Jasper Therapeutics. Prior to that, he was chief medical officer at NextCure, Inc., a biotechnology company developing immunotherapy-based biologics for cancer and other diseases. Before that, he was vice president and head of antibody clinical development at Incyte, coordinating immunotherapy clinical development strategies for multiple antibody programs. He joined Incyte from AstraZeneca, where he was senior medical director, overseeing global medicines development in oncology.
- **01.18.23 - Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors (PR)**
  - Mr. Dobmeier brings over two decades of experience leading biotech companies through key periods of growth. He currently serves as CEO of Chinook Therapeutics, focused on the development of novel therapies for kidney disease, where he led the company's transition from private to public and raised over \$500 million in capital. Prior to this, Mr. Dobmeier held successive leadership positions at Seattle Genetics, including Chief Operating Officer and Chief Business Officer. While at Seattle Genetics, he was directly involved in raising more than \$1.2 billion and completed multiple corporate alliances with leading biotechnology and pharmaceutical companies. He currently serves on the board of Atara Therapeutics. Dr. Waldstreicher brings over 30 years of experience in various clinical and strategic leadership roles at Johnson & Johnson and Merck & Co. As Chief Medical Officer at Johnson & Johnson, she provides critical leadership in late-stage clinical development in metabolism and cardiovascular disease as well as other therapeutic areas.
- **01.17.23 - Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader (PR)**
  - Mr. Zayas will be responsible for all of the company's North American biologics operations, including its centers of excellence for drug product fill/finish in Bloomington, Indiana, and gene therapy manufacturing in Harmans, Maryland. He will serve on the Executive Leadership Team, reporting directly to Catalent's President & Chief Executive Officer, Alessandro Maselli. Mr. Zayas' experience includes more than 30 years working in pharmaceutical manufacturing and operations leadership. He joins Catalent from Ocyonbio, a biosimilars, cell and gene, and viral vector development and manufacturing company, where he was Chief Operating Officer. Prior to that, as Executive Vice President and Head of Operations for Romark Pharmaceuticals, he led the development and buildout of Romark's new manufacturing facility in Puerto Rico. His career also includes seven years at Bristol-Myers Squibb, where he held the position of Senior Vice President, Global Pharmaceutical Manufacturing, Supply Chain, and Product Strategy, and led global pharmaceutical and API manufacturing, overseeing more than 8,000 employees worldwide. He has also held pharmaceutical manufacturing leadership roles at Sterling Drug, Warner-Lambert, Pfizer, Schering Plough, AMAG Pharmaceuticals, and Avon Products.

- **01.10.23 - Novavax Names John C. Jacobs as New President & Chief Executive Officer (Pharmatechfocus)**
  - Mr. Jacobs brings more than 25 years of commercial, operations, business and leadership experience across multiple therapeutic areas. He will join Novavax from Harmony Biosciences, where he has served as President and Chief Executive Officer and a member of the Board of Directors since June 2018, and Executive Vice President and Chief Commercial Officer from October 2017 to June 2018. Notably, Mr. Jacobs led the company through a successful IPO and led its first product through FDA review, approval and commercialization. Prior to joining Harmony, Mr. Jacobs held leadership roles at Teva Pharmaceuticals beginning in 2014, including Senior Vice President and General Manager of the Respiratory Business Unit, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada. Mr. Jacobs has also held positions of increasing scope and responsibility at major pharmaceutical companies including Cephalon, Wyeth and Pfizer. He received a B.S. in business from State University of New York College at Plattsburgh and an M.B.A. from The State University of New York at Binghamton.
- **01.10.23 - Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy (PR)**
  - Patrick brings over 25 years of experience in building commercial teams, leading global product launches, and developing strategic plans to ensure the success of both large and small pharmaceutical companies. Most recently he served as VP, Commercial at Iovance Biotherapeutics, where he was responsible for all pre-launch commercial activities for the first cell therapy for melanoma and cervical cancer. Prior to Iovance, Patrick held commercial roles of increasing responsibility at Gilead Sciences, notably playing a key role in launching Gilead's SOVALDI® and HARVONI® for HCV, as well as leading commercial planning for the company's liver disease portfolio. Patrick received his M.B.A. from the University of California, Water A. Haas School of Business.
- **01.09.22 - Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development (PR)**
  - Dr. Williamson brings more than 20 years of research, development, and commercial experience to his new role. Most recently, Dr. Williamson served as Chief Medical Officer at Avadel Pharmaceuticals. Prior to that, he served as Senior Vice President, Head of U.S. Research and Development and Deputy Global Chief Medical Officer at Lundbeck, where he led a transformation of the U.S. Research and Development organization and oversaw multiple cross-functional teams across clinical development and operations, medical affairs, health outcomes, pharmacovigilance, clinical pharmacology and regulatory affairs.
- **01.09.22 - ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer (PR)**
  - Dr. MacLeod joins ADARx as ADX-324 for the treatment of hereditary angioedema is currently enrolling healthy volunteers for its phase I clinical trial. ADARx has two additional drug candidates set to enter clinical trials in 2023 and an extensive pipeline to follow. Prior to ADARx, Dr. MacLeod served as the Chief Scientific Officer at Flamingo Therapeutics after holding several positions at Ionis Pharmaceuticals, most recently as Vice President and Franchise Head of Oncology. He has led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of 15 novel investigational therapeutics and over 100 high impact scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University in Montreal Canada, and his Ph.D. in Cancer Epigenetics from McGill University.
- **01.09.23 - Atreca Appoints Philippe Bishop, MD as Chief Medical Officer (PR)**
  - Dr. Bishop joins Atreca from Clover Biopharmaceuticals, a global biotech company focused on the development of vaccines and biologics, where he served as CMO. Previously, he was Executive Vice President and CMO at aratinga.bio, a developer of novel cancer immunotherapies. Before founding aratinga.bio in 2017, Dr. Bishop was Senior Vice President Hematology / Oncology at Gilead Sciences and held clinical development roles at Genentech, Johnson & Johnson and Sanofi-Aventis. Prior to his industry career, he held leadership positions at the U.S. Food and Drug Administration and National Institutes of Health. Dr. Bishop received his M.D. from the University of Nevada School of Medicine followed by a residency in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute.

## About Berke Search

The Berke Executive Search team is comprised of seasoned and engaged partners who lead our highly specialized firm with an unwavering commitment to excellence and integrity. With over two decades of experience conducting searches for C-Suite, Senior Commercial, Scientific Leadership, and specialized functional leadership disciplines, we have developed deep relationships and a large network of top talent. Our deep experience and expertise benefits clients by shrinking timelines and lowering talent acquisition costs. In addition, our nimble size (boutique) and highly selective client base virtually eliminate conflict of interest and off-limit issues; we execute only a select number of search pools to ensure our resources are maximized and enable superior success rates.

Visit us at [Berkesearch.com](https://www.berkesearch.com)